GlassScriptPhysician profile
Jamie Widawsky
NPI 1780943076
$36,374.79
in general payments reported to CMS, 2019-2025
18 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,597 · 2022: $5,635 · 2023: $6,163 · 2024: $9,119 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,014 · Travel and Lodging: $973 · Education: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,417.50 |
| Food and Beverage | $10,249.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,013.70 |
| Travel and Lodging | $973.03 |
| Education | $489.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,119.18 | 2021-2025 | |
| Leo Pharma INC. | $5,408.87 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $4,616.94 | 2021-2025 | |
| Eli Lilly and Company | $4,053.52 | 2025 | Ebglyss |
| Regeneron Healthcare Solutions, INC. | $3,671.71 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $1,848.94 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Genzyme Corporation | $1,621.39 | 2021-2025 | |
| Janssen Biotech, INC. | $1,589.75 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,556.30 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,508.14 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $1,488.60 | 2023-2025 | Zoryve |
| Incyte Corporation | $1,141.00 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $852.25 | 2022-2025 | Sotyktu |
| Organon LLC | $354.84 | 2025 | Vtama |
| Amgen INC. | $324.65 | 2021-2023 | Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $122.55 | 2024 | Dupixent |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Ucb, INC. | $43.16 | 2024-2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Widawsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.